Consistency of a two clinical site sample collection: A proteomics study

Proteomics - Clinical Applications

Volumn 4, Issue 8-9, 2010, Pages 726-738

  Wiesner, Cedric ^a   Hannum, Charles ^a   Reckamp, Karen ^b   Figlin, Robert ^b   Dubridge, Robert ^a   Roy, Sushmita Mimi ^c   Lin, Shanhua ^c   Becker, Christopher H ^c   Jones, Ted ^c   Hiller, Jordan ^a   Cheville, John C ^d   Wilson, Keith ^a  

^a Facet Biotech   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Caprion Proteomics US   (United States)

^d MAYO CLINIC   (United States)

Author keywords

2 D LC MS; Data reproducibility; Sample collection; Sample handling

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; FEMALE; FUNCTIONAL PROTEOMICS; GENETIC ALGORITHM; HUMAN; KIDNEY CANCER; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; VALIDATION PROCESS;

BIOLOGICAL MARKERS; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PRINCIPAL COMPONENT ANALYSIS; PROTEOMICS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TIME FACTORS;

EID: 78650440026     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900206     Document Type: Article

References (38)

1. Beretta, L., Proteomics from the clinical perspective: many hopes and much debate. Nat. Methods 2007, 4, 785-786.
2. Kumar, S., Mohan, A., Guleria, R., Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 2006, 11, 385-405.
3. deVera, I. E., Katz, J. E., Agus, D. B., Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. Clin. Adv. Hematol. Oncol. 2006, 4, 541-549.
4. Lee, J. W., Figeys, D., Vasilescu, J., Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv. Cancer Res. 2007, 96, 269-298.
5. Ransohoff, D. F., Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 2004, 4, 309-314.
6. Zolg, J. W., Langen, H., How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 2004, 3, 345-354.
7. Diamandis, E. P., Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst. 2004, 96, 353-356.
8. Feng, Z., Prentice, R., Srivastava, S., Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004, 5, 709-719.
9. Gao, J., Garulacan, L. A., Storm, S. M., Opiteck, G. J. et al., Biomarker discovery in biological fluids. Methods 2005, 35, 291-302.
10. Qian, W. J., Jacobs, J. M., Liu, T., Camp, D. G., 2nd Smith, R. D., Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell. Proteomics 2006, 5, 1727-1744.
11. Liu, J. P., Chow, S. C., Statistical issues on the diagnostic multivariate index assay for targeted clinical trials. J. Biopharm. Stat. 2008, 18, 167-182.
12. Simon, R., Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 2005, 23, 7332-7341.
13. Simon, R., Radmacher, M. D., Dobbin, K., McShane, L. M., Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl. Cancer Inst. 2003, 95, 14-18.
14. Dupuy, A., Simon, R. M., Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J. Natl. Cancer Inst. 2007, 99, 147-157.
15. Baggerly, K. A., Morris, J. S., Edmonson, S. R., Coombes, K. R., Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl. Cancer Inst. 2005, 97, 307-309.
16. Hu, J., Coombes, K. R., Morris, J. S., Baggerly, K. A., The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct. Genomic Proteomic 2005, 3, 322-331.
17. Nesvizhskii, A. I., Vitek, O., Aebersold, R., Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat. Methods 2007, 4, 787-797.
18. Petricoin, E. F., Fishman, D. A., Conrads, T. P., Veenstra, T. D., Liotta, L. A., Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics 2004, 4, 2357-2360.
19. Villanueva, J., Philip, J., Chaparro, C. A., Li, Y. et al., Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 2005, 4, 1060-1072.
20. West-Nielsen, M., Hogdall, E. V., Marchiori, E., Hogdall, C. K. et al., Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem. 2005, 77, 5114-5123.
21. Roy, S., Josephson, S. A., Fridlyand, J., Karch, J. et al., Protein biomarker identification in the CSF of patients with CNS lymphoma. J. Clin. Oncol. 2008, 26, 96-105.
22. Bell, A. W., Deutsch, E. W., Au, C. E., Kearney, R. E. et al., A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat. Methods 2009, 6, 423-430.
23. Roy, S., Anderle, M., Lin, H., Becker, C., Differential expression profiling of serum proteins and metabolites for biomarker discovery. Int. J. Mass Spectrom. 2004, 238, 163-171.
24. Wang, W., Zhou, H., Lin, H., Roy, S. et al., Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal. Chem. 2003, 75, 4818-4826.
25. Roy, S. M., Becker, C. H., Quantification of proteins and metabolites by mass spectrometry without isotopic labeling. Methods Mol. Biol. 2007, 359, 87-105.
26. Anderle, M., Roy, S., Lin, H., Becker, C., Joho, K., Quantifying reproducibility for differential proteomics: noise analysis for protein liquid chromatography-mass spectrometry of human serum. Bioinformatics 2004, 20, 3575-3582.
27. Keller, A., Nesvizhskii, A. I., Kolker, E., Aebersold, R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74, 5383-5392.
28. Krokhin, O. V., Craig, R., Spicer, V., Ens, W. et al., An improved model for prediction of retention times of tryptic peptides in ion pair reversed-phase HPLC: its application to protein peptide mapping by off-line HPLC-MALDI MS. Mol. Cell. Proteomics 2004, 3, 908-919.
29. Storey, J. D., Tibshirani, R., Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 2003, 100, 9440-9445.
30. Troyanskaya, O., Cantor, M., Sherlock, G., Brown, P. et al., Missing value estimation methods for DNA microarrays. Bioinformatics 2001, 17, 520-525.
31. Li, J., Bushel, P., Chu, T.-M., Wolfinger, R. D., in: Scherer, A. (Ed.), Estimating Batch Effects in Microarray Gene Expression Data, Batch Effects and Noise in Microarray Experiments: Sources and Solutions, John Wiley & Sons 2009.
32. Trevino, V., Falciani, F., GALGO: an R package for multivariate variable selection using genetic algorithms. Bioinformatics 2006, 22, 1154-1156.
33. O'Riordan, E., Gross, S. S., Goligorsky, M. S., Technology Insight: renal proteomics - at the crossroads between promise and problems. Nat. Clin. Pract. Nephrol. 2006, 2, 445-458.
34. Jabs, W. J., Busse, M., Kruger, S., Jocham, D. et al., Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005, 68, 2103-2110.
35. Kimura, M., Tomita, Y., Imai, T., Saito, T. et al., Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 2001, 92, 2072-2075.
36. Tolson, J., Bogumil, R., Brunst, E., Beck, H. et al., Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest. 2004, 84, 845-856.
37. Ljungberg, B., Grankvist, K., Rasmuson, T., Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995, 76, 1435-1439.
38. Kosari, F., Parker, A. S., Kube, D. M., Lohse, C. M. et al., Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res. 2005, 11, 5128-5139.